MD001 alleviated fatty liver by reducing TG and FFA levels in db/db mice, which was associated with increased expression levels of ACOX, CPT, and MLYCD and decreased expression levels of ADD1, ACC, and FAS by PPARα activation. Here, ADD1 is linked to Hepatic steatosis.